Literature DB >> 11369298

Temporal relationships among uterine pituitary adenylate cyclase-activating polypeptide, decidual prolactin-related protein and progesterone receptor mRNAs expressions during decidualization and gestation in rats.

F Spencer1, L Chi, M Zhu.   

Abstract

Pituitary adenylate cyclase-activating peptide (PACAP), a novel compound with vasoactive intestinal polypeptide-like activity, was recently shown to be localized in the neuronal endings of the human uterus. The purpose of the present study was to assess the functional presence of PACAP mRNA in the decidual endometrium and its relationship to the expression levels of decidual prolactin-related protein (dPRP) and the progesterone receptor mRNAs during decidualization and pregnancy in Sprague-Dawley rats. PACAP was constitutively and temporally expressed in the decidual endometrium and gravid uterus. The time-dependent correlated expression levels of PACAP, dPRP and the progesterone receptor were induced by the neurogenic reproductive signals, i.e. the vagino-cervical/deciduogenic stimuli of decidualization and by the normal equivalent stimuli of mating/blastocyst implantation of gestation. Correlation among the mRNA expression levels of PACAP, dPRP and the progesterone receptor and the coordinated inhibitory actions of the anti-progesterone (RU-486) suggest that there is also correlated time-dependent steroid regulation of the mRNA levels of PACAP, dPRP and the progesterone receptor in the decidual and pregnant uteri. One possible functional meaning for the time-related localization of endometrial/uterine PACAP could be to facilitate endometrial blood flow and increase the availability of metabolic substrates to the developing deciduoma or embryo. The study demonstrates the potential importance of PACAP expression in the regulation of the maternal feto-placental component and suggests a prominent reproductive role for the neuropeptide in mammalian pregnancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369298     DOI: 10.1016/s1532-0456(01)00177-6

Source DB:  PubMed          Journal:  Comp Biochem Physiol C Toxicol Pharmacol        ISSN: 1532-0456            Impact factor:   3.228


  4 in total

1.  Alterations of pituitary adenylate cyclase-activating polypeptide-like immunoreactivity in the human plasma during pregnancy and after birth.

Authors:  D Reglodi; J Gyarmati; T Ertl; R Borzsei; J Bodis; A Tamas; P Kiss; K Csanaky; E Banki; C Bay; J Nemeth; Z Helyes
Journal:  J Endocrinol Invest       Date:  2010 Jul-Aug       Impact factor: 4.256

2.  Changes in the expression of pituitary adenylate cyclase-activating polypeptide in the human placenta during pregnancy and its effects on the survival of JAR choriocarcinoma cells.

Authors:  R Brubel; A Boronkai; D Reglodi; B Racz; J Nemeth; P Kiss; A Lubics; G Toth; G Horvath; T Varga; D Szogyi; E Fonagy; J Farkas; A Barakonyi; Sz Bellyei; L Szereday; M Koppan; A Tamas
Journal:  J Mol Neurosci       Date:  2010-05-07       Impact factor: 3.444

3.  Investigation of the possible functions of PACAP in human trophoblast cells.

Authors:  G Horvath; D Reglodi; R Brubel; M Halasz; A Barakonyi; A Tamas; E Fabian; B Opper; G Toth; M Cohen; L Szereday
Journal:  J Mol Neurosci       Date:  2014-05-30       Impact factor: 3.444

Review 4.  Female reproductive functions of the neuropeptide PACAP.

Authors:  Miklos Koppan; Zsuzsanna Nagy; Inez Bosnyak; Dora Reglodi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-20       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.